Core Laboratories Inc. (CLB) Stock Price & Analysis
Core Laboratories Inc. (CLB) closed at USD 10.49 on Wednesday, October 28, 2026, up 1.55% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.49; the Oct 28, 2026 session ranged USD 10.26–10.61 on volume of 976,970 shares. Market capitalization is —, with a 52-week range of USD 9.13–20.36 (NYQ). Source: Nexqual, retrieved October 29, 2026 at 07:45 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CLB.md
Latest Earnings Results (CLB)
Core Laboratories Inc. (CLB) reported Q3 2026 results on Oct 28, 2026, 4:22:55 PM ET: adjusted EPS $0.16 vs. estimate $0.16 (in line), revenue $132.08M vs. estimate $132.14M (miss). Guidance: The company did not provide specific numerical guidance for the next quarter or full year. Source: SEC 8-K filing. Nexqual published it 30 seconds after release. Read the SEC filing.
| Fiscal period | EPS (reported) | Revenue | Released | Source |
|---|---|---|---|---|
| Q3 2026 | $0.16 (adjusted (non-GAAP) diluted) | $132.1M | Oct 28, 2026, 4:22:55 PM ET · on Nexqual +30 seconds | SEC 8-K filing |
Reported actuals captured by Nexqual from SEC 8-K filings and company press releases; each figure confirmed by two independent extraction methods.
Key facts (CLB)
- Last four reported quarters (through Jun 30, 2026): revenue $519M, net income $24.4M (4.7% margin), free cash flow $15.1M (SEC filings).
- 1 of 80 tracked superinvestors hold CLB (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $54K; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -34.7% vs S&P 500 +13.6%; 5Y -59.2% vs S&P 500 +79.8%.
- Next earnings: 2026-10-28, EPS estimate USD 0.16, revenue estimate $132M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CLB)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $470M | $490M | $510M | $524M | $527M | $519M |
| Gross profit | — | $96.1M | $110M | $103M | $109M | — |
| Operating income | $45.3M | $41.5M | $54.6M | $58.6M | $56.5M | $47.8M |
| Net income | $19.7M | $19.5M | $36.7M | $31.4M | $29.7M | $24.4M |
| EPS (diluted) | $0.42 | $0.42 | $0.77 | $0.66 | $0.63 | — |
| Free cash flow | $23.0M | $14.7M | $14.2M | $44.5M | $25.8M | $15.1M |
| Gross margin | — | 19.6% | 21.5% | 19.7% | 20.7% | — |
| Operating margin | 9.6% | 8.5% | 10.7% | 11.2% | 10.7% | 9.2% |
| Net margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% | 4.7% |
| Revenue growth | — | +4.1% | +4.1% | +2.8% | +0.5% | — |
| Cash + short-term investments | $17.7M | $15.4M | $15.1M | $19.2M | $22.7M | — |
| Total debt | — | $175M | $166M | $128M | $113M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CLB)
P/E at fiscal year-ends: Dec 2025 25.4x, Dec 2024 26.3x, Dec 2023 22.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (CLB)
1 of 80 tracked investors hold CLB. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| John Rogers | Ariel Investments | 1.63% | $164M | Added +6.9% |
Insider purchases (SEC Form 4, open-market, last ~7 months) (CLB)
1 purchase, $54K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-07-31 | Bruno Lawrence | Chairman and CEO | 5,000 | $54K | 10.78 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Total return (dividends reinvested) (CLB)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -34.7% | -59.2% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -34.8% | -16.4% |
| Volatility (annualized) | 46.4% | 54.5% |
| Max drawdown | -52.1% (Jan 2026→Oct 2026) | -70.2% (Apr 2022→Oct 2026) |
CLB earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.11 | $0.09 | Beat +22.2% | — |
| — | Quarter ended Mar 31, 2026 | $0.06 | $0.11 | Miss −45.5% | — |
| — | Quarter ended Dec 31, 2025 | $0.21 | $0.19 | Beat +10.5% | — |
| — | Quarter ended Sep 30, 2025 | $0.22 | $0.19 | Beat +15.8% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CLB recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 28, 2026 | 8-K | Quarterly results; Regulation FD disclosure |
| Aug 25, 2026 | 8-K | Director or executive officer change, or pay arrangement “On August 19, 2026, Kwaku Temeng verbally notified the Board of Directors of Core Laboratories Inc. (the "Company") of his intention to resign as a director of the Company effective October 1, 2026. Subsequently, on August 25, 2026, Mr. Temeng confirmed his resignation by letter addressed to the Board of Directors. Mr. Temeng serves as Chairman of the Nominating Committee and as a member of the Compensation Committee. As stated in his letter, Mr. Temeng's resignation was due to a disagreement with the Board of…” |
| Aug 14, 2026 | Schedule 13G/A | DISCIPLINED GROWTH INVESTORS INC /MN: 6.6% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | Schedule 13G/A | Ariel Investments, LLC: 30.5% of shares, passive 5%+ holder (amended) |
| Aug 6, 2026 | Schedule 13G/A | BlackRock, Inc.: 8.3% of shares, passive 5%+ holder (amended) |
| Jul 30, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Jul 29, 2026 | 8-K | Quarterly results; Regulation FD disclosure |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
CLB revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Operating Segment Reservoir Description | $78.7M | 63.2% | -8.7% |
| Operating Segment Production Enhancement | $45.9M | 36.8% | +4.5% |
| Total revenue | $124.6M | 100% | — |
CLB revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Service | $94.3M | 75.7% | -2.0% |
| Product | $30.3M | 24.3% | -10.6% |
| Total revenue | $124.6M | 100% | — |
CLB revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Non Us | $351.2M | 66.7% | +1.8% |
| United States | $175.3M | 33.3% | -2.0% |
| Total revenue | $526.5M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CLB company outlook (results filed Oct 28, 2026)
- “Outlook and Guidance Ongoing geopolitical conflicts in the Middle East and Russia-Ukraine, along with associated sanctions, continued to disrupt the transportation and trading of crude oil and refined products during the third quarter of 2026.”
- “Looking ahead, the IEA, EIA and OPEC all anticipate strong global crude oil demand growth in 2027 as supply disruptions ease and trade flows normalize.”
- “For the fourth quarter of 2026, Core Lab expects revenue to remain relatively flat sequentially, reflecting continued disruptions in the Middle East.”
Quoted word-for-word from the SEC 8-K results press release.
CLB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.16 | $0.15 | +3.2% | $132.1M | 3 |
| Next quarter (ends Dec 2026) | $0.17 | $0.21 | -19.0% | $133.3M | 3 |
| Current fiscal year (ends Dec 2026) | $0.51 | $0.54 | -6.2% | $511.9M | 3 |
| Next fiscal year (ends Dec 2027) | $0.69 | $0.85 | -19.3% | $524.8M | 3 |
Key Statistics (as of October 29, 2026 at 07:45 UTC)
| Price | USD 10.49 |
|---|---|
| Change | ▲ 1.55% (up) |
| Previous Close | USD 10.49 |
| Open | USD 10.49 |
| Day Range | USD 10.26 – 10.61 |
| 52-Week Range | USD 9.13 – 20.36 |
| Volume | 976,970 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (CLB)
Nexqual's technical model rates CLB "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 07:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.69 (neutral) |
| vs SMA50 | Below (USD 11.07) |
| MACD | -0.2 (negative) |
Earnings (CLB)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 0.16 |
| Revenue Estimate | $132.14M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.11 vs est 0.09 ▲ beat |
| 2026-03-31 | USD 0.06 vs est 0.11 ▼ miss |
| 2025-12-31 | USD 0.21 vs est 0.19 ▲ beat |
| 2025-09-30 | USD 0.22 vs est 0.19 ▲ beat |
Source: Nexqual, October 29, 2026 at 07:45 UTC.
Financials & Fundamentals (CLB)
| Total Revenue | $519.18M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -4.30% |
| Gross Margin | +19.52% |
| Operating Margin | +7.36% |
| Profit Margin | +4.69% |
| ROE | +9.05% |
| Debt / Equity | 0.59 |
| Current Ratio | 2.12 |
| Total Cash | $22.73M |
| Total Debt | $165.12M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $15.14M (2.9% of revenue) |
Source: Nexqual, October 29, 2026 at 07:45 UTC.
Financial Health Score (CLB)
Nexqual rates Core Laboratories Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 07:45 UTC.
| Growth | Mixed — Revenue +0.5% YoY (annual), slow |
|---|---|
| Profitability | Mixed — Gross margin 20%, operating 9% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Strong — $23M cash and investments vs $116M debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $15M (last 4 quarters to Jun 2026, SEC), slim 2.9% margin |
| Efficiency | Mixed — ROE 9%, ROA 4.2% (last 4 quarters, SEC) |
Ownership (CLB)
| Insider Ownership | +1.43% |
|---|---|
| Institutional Ownership | +113.98% |
| Shares Outstanding | 45.88M |
| Float | 45.23M |
| Short % of Float | +25.69% |
Source: Nexqual, October 29, 2026 at 07:45 UTC.
From Core Laboratories Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- We were established in 1936 and are one of the world's leading providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry, primarily through client relationships with many of the world's major, national and independent oil companies.
- While we have patented some of our key technologies, we do not patent all of our proprietary technology even where regarded as patentable.
- We also use our proprietary services and technologies to correlate the reservoir description data to wireline logs and other subsurface data.
- Our databases, technology and analytical methods also allow us to assist our clients in other ways.
Legal & Regulatory Risks (Item 1A, quoted)
- Our operations may be adversely affected by sanctions, export controls, and similar measures targeting Russia and other countries and territories as well as other responses to Russia's military conflict in Ukraine.
- Our results of operations may be adversely affected because our efforts to comply with applicable anti-corruption laws such as the United States' Foreign Corrupt Practices Act (the "FCPA") and the United Kingdom's Anti-Bribery Act (the "ABA") could restrict our ability to do business in foreign markets relative to our competitors who are not subject to these laws.
- New or amended legislation, executive actions, regulations or other regulatory initiatives that impose more stringent oil and gas sector requirements or fees on GHG emissions or restrict the areas in which this sector may produce oil and natural gas or generate GHG emissions could result in increased compliance costs or costs of producing fossil fuels.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TTI | Tetra Technologies, Inc. | USD 6.03 | ▲ 4.87% |
| ACDC | ProFrac Holding Corp. | USD 4.99 | ▲ 8.71% |
| FTK | Flotek Industries, Inc. | USD 26.08 | ▲ 1.12% |
| PUMP | ProPetro Holding Corp. | USD 7.76 | ▲ 2.65% |
| FET | Forum Energy Technologies, Inc. | USD 90.91 | ▲ 1.07% |
| AESI | Atlas Energy Solutions Inc. | USD 9.44 | ▲ 3.96% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:45 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt